Report updated results from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 21 Mar 2024
- Due
- 30 Jun 2024
- Delivered
- by 13 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“updated results from phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) 1H’24”
What we found
Evidence strength A What the grades mean
The company presented updated Phase 1b data for DISC-0974 in anemia of myelofibrosis at the European Hematology Association (EHA) 2024 Congress, which took place in June 2024.
-
A Disc Medicine, Inc. 8-K filed 2024-08-08
“Presented updated Phase 1b data from DISC-0974 in anemia of MF patients demonstrating a durable hemoglobin response in the majority of patients” ✓ confirmed on the page
Market reaction: the shares moved +6.3% against the S&P 500 over the three sessions around the disclosure (7 Aug 2024 to 12 Aug 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +914 days
- 4 versions
-
Version 1 · original · stated 21 Mar 2024
Deadline 30 Jun 2024 (“1H’24”)
-
Version 2 · stated 9 May 2024
Deadline 30 Jun 2024 (“Q2 2024”) · wording expected
“Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF)... in Q2 2024”
-
Version 3 · stated 7 May 2025
Deadline 31 Dec 2025 (“H2 2025”) · wording expected
“Expect data readouts for DISC-0974 program in H2 2025, including initial results of Phase 2 anemia of myelofibrosis (MF) study”
-
Version 4 · stated 12 Jan 2026
Deadline 31 Dec 2026 (“in H2 2026”) · wording expected
“Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- DISC-0974 phase 1b/2 study updated results
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-IRON-002158 · Corrections policy